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Abstract 
Background: Recent reports highlight malaria as a frequent diagnosis in migrants who originate from Eritrea. A 
descriptive analysis of GeoSentinel cases of malaria in Eritrean migrants was done together with a literature review to 
elucidate key attributes of malaria in this group with a focus on possible areas of acquisition of malaria and treatment 
challenges.
Results: A total of 146 cases were identified from the GeoSentinel database from 1999 through September 2017, 
with a marked increase in 2014 and 2015. All patients originated from Eritrea and the main reporting GeoSentinel sites 
were in Norway, Switzerland, Sweden, Israel and Germany. The majority of patients (young adult males) were diag-
nosed with malaria following arrival in the host country. All patients had a possible exposure in Eritrea, but may have 
been exposed in documented transit countries including Ethiopia, Sudan and possibly Libya in detention centres. 
Most infections were due to Plasmodium vivax (84.2%), followed by Plasmodium falciparum (8.2%). Two patients were 
pregnant, and both had P. vivax malaria. Some 31% of the migrants reported having had malaria while in transit. The 
median time to onset of malaria symptoms post arrival in the host country was 39 days. Some 66% of patients were 
hospitalized and nine patients had severe malaria (according to WHO criteria), including five due to P. vivax.
Conclusions: The 146 cases of mainly late onset, sometimes severe, P. vivax malaria in Eritrean migrants described 
in this multi-site, global analysis reflect the findings of single-centre analyses identified in the literature search. Host 
countries receiving asylum-seekers from Eritrea need to be prepared for large surges in vivax and, to a lesser extent, 
falciparum malaria, and need to be aware and prepared for glucose-6-phosphate dehydrogenase deficiency testing 
and primaquine treatment, which is difficult to procure and mainly unlicensed in Europe. There is an urgent need to 
explore the molecular epidemiology of P. vivax in Eritrean asylum-seekers, to investigate the area of acquisition of P. 
vivax along common transit routes and to determine whether there has been re-introduction of malaria in areas, such 
as Libya, where malaria is considered eliminated, but where capable vectors and Plasmodium co-circulate.
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Background
Conflict-related migration challenges health systems 
in host countries and population movements have an 
impact on infectious disease epidemiology. Migrants 
present to local medical facilities in host countries with 
unfamiliar infectious diseases that may require unli-
censed treatments. These circumstances have implica-
tions for screening, diagnostics, medication procurement 
and adherence to treatment. Several reports have high-
lighted that malaria is a frequent diagnosis in migrants, 
who originate in Eritrea [1–3] and who transit coun-
tries in sub-Saharan and northern Africa. National 
malaria surveillance statistics show a marked increase in 
imported malaria in asylum seekers [3, 4]. Migrants from 
Eritrea encompass both refugees and asylum-seekers. An 
asylum-seeker is an individual who has sought interna-
tional protection and whose claim for refugee status has 
not yet been determined [5]. Countries are responsible 
for determining whether an asylum-seeker is a refugee or 
not. Eritrea is considered to be one of the world’s “fastest 
emptying nations” mainly due to forced army conscrip-
tion that may last a lifetime. Eritrea ranks 5th in the top 
ten origins of persons applying for asylum in the Euro-
pean Union [5].
The United Nations High Commissioner for Refu-
gees (UNHCR) reported 474,296 Eritreans globally to 
be refugees and asylum-seekers [5]. This constitutes 
approximately 12% of Eritrea’s official 3.6 million popu-
lation estimate as of 2015. Using the dual approach of a 
GeoSentinel global database descriptive analysis and an 
in-depth literature review, this analysis describes malaria 
in Eritreans presenting at GeoSentinel sites and evaluates 
the complexity of presentation and treatment in this dis-
tinct group of migrants.
Methods
GeoSentinel (http://www.geose ntine l.org) sites are clinics 
specializing in travel, migration and/or tropical medicine, 
that contribute clinician-based data on ill migrants and 
travellers to a global database. To be eligible for inclusion 
in the database, the patient must have crossed an inter-
national border in the 10 years prior to presentation and 
the diagnosis must be considered “travel-related” by the 
reporting GeoSentinel clinician [6]. GeoSentinel’s data 
collection protocol has been reviewed by the institu-
tional review board officer at CDC’s National Center for 
Emerging and Zoonotic Infectious Diseases and is classi-
fied as public health surveillance and not human subject 
research. When indicated by national regulations at indi-
vidual GeoSentinel sites, additional ethical clearance has 
been obtained.
Only symptomatic Eritrean migrants with con-
firmed malaria diagnoses were included in this analysis. 
Clinical data captured included the presenting symp-
toms, malaria species identification, severity of infection 
and in-patient/out-patient status. ‘Severe malaria’ was 
defined according to World Health Organization (WHO) 
criteria [7]. Demographic data were also collated: age, 
sex, country of birth, and country of residence/asylum, 
travel history (arrival date and transit routes when avail-
able). GeoSentinel sites use the best reference diagnostic 
tests available and screen for glucose-6-phosphate dehy-
drogenase (G6PD) deficiency; the malaria cases in this 
study were based on presence of malaria symptoms and 
confirmation by microscopy or PCR or RDT.
In addition to the descriptive analysis of the GeoSenti-
nel database, a literature review was done. The databases 
PubMed, Embase and Scopus were searched using the 
word combinations “malaria”, “migrant”, “Eritrea”. Articles 
in English, German, Italian and French were included. 
Relevant reports from public health agencies, ministries 
and malaria surveillance statistics were also screened. 
The time period for the database searches was January 
1st 2010 to July 31st 2018. GeoSentinel Sites that con-
tributed cases to this analysis, were queried regarding the 
availability of primaquine and G6PDH deficiency testing 
at their sites.
Results
There were 146 cases identified from the GeoSenti-
nel database from 1999 through September 15, 2017 
(Fig. 1), with a marked increase in 2014 and 2015. There 
was a 66% hospitalization rate and 9 cases of severe 
malaria. No death was recorded. All patients origi-
nated from Eritrea and were diagnosed with malaria 
following their initial migration trip with the main 
reporting sites in Norway, Switzerland, Sweden, Israel 
and Germany (Table  1) in descending order of contri-
bution. The majority of the patients were young adult 
males. The migration route was not documented for 
all patients (Table  2), but most of them were possi-
bly also exposed in other transit countries, including 
notably Sudan 76% (41/54) and Ethiopia 57% (31/54). 
Additionally, 34 patients 63% (34/54) declared hav-
ing transited Libya during their migration trip, 7 tran-
sit routes led through Egypt, one through Syria, one 
through Turkey and one through Uganda. Most infec-
tions were due to Plasmodium vivax (84.2%), followed 
by Plasmodium falciparum (8.2%), Plasmodium ovale 
(2.7%), Plasmodium malariae (0.7%), and unspecified 
species or mixed infection (Table 3). Most patients had 
the onset of malaria symptoms after arriving in the host 
country (median 39  days) and consulted a median of 
3  days following symptom onset. About a third (31%) 
of the migrants reported having had malaria while in 
transit. All patients were symptomatic and the most 
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common presenting symptoms were fever (98.0%), gas-
trointestinal (9.6%), fatigue (8.2%), headaches (7.5%) 
and respiratory symptoms (6.9%). Two patients (aged 
20 and 21 years, respectively) with P. vivax malaria were 
pregnant. Nine patients were reported to have severe 
malaria (Table  3), including: P. vivax infection with 
severe anaemia (n = 3), P. vivax infection with renal fail-
ure (n = 1), P. vivax infection with cardiovascular fail-
ure (n = 1), P. falciparum infection with severe anaemia 
(n = 1), P. falciparum infection with hyperparasitaemia 
and respiratory failure, unknown malaria species infec-
tion with neurological symptoms (n = 1) and unknown 
species infection with cardiovascular failure (n = 1). The 
survey of GeoSentinel sites showed that primaquine 
is unregistered and difficult to procure in Europe but 
available in the USA and Canada and that the speed of 
G6PDH deficiency testing is variable (Additional file 1). 
The literature review, identified 10 papers that refer to 
malaria in Eritrean migrants.
Fig. 1 Flow chart of the GeoSentinel “Malaria in Eritrean Migrants” analysis
Table 1 Demographics
Country of origin Eritrea malaria cases
n = 146 (100.0%)
Country of immigration (Host country)
 Norway 35 (24.0%)
 Switzerland 31 (21.2%)
 Sweden 25 (17.1%)
 Israel 19 (13.0%)
 Germany 17 (11.6%)
 Denmark 7 (4.8%)
 Belgium 5 (3.4%)
 UK 4 (2.7%)
 USA 2 (1.4%)
 Canada 1 (0.7%)
Gender
 Male 114 (78.1%)
 Female 32 (21.9%)
 M/F ratio 3.6
Age
 Mean (SD) 22.9 years (7.5 years)
 Median (range) 22 years (4–55 years)
 < 15 years 5 (3.4%)
Table 2 Transit and possible exposure countries
Possible country of exposure besides Eritrea  
(Transit countries)
Sudan 43 (29.5%)
Libya 34 (23.3%)
Ethiopia 31 (21.2)
Egypt 7 (5.0%)
Syria 1 (0.7%)
Turkey 1 (0.7%)
Uganda 1 (0.7%)
Not documented 92 (63.0%)
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Discussion
This descriptive analysis of malaria cases ex Eritrea 
notified to GeoSentinel shows that the majority of cases 
were P. vivax (84%) and the median time to presenta-
tion after arrival in the host country was 39  days (for 
those for whom data were available). These results 
mirror the findings of single centre studies in Europe 
[1–4, 8, 10–12, 32]. and Israel [2] and reflect a shift in 
imported malaria species dominance in Europe due to 
the changing demographics of migrants and asylum 
seekers. Prior to 2013, P. falciparum was the predomi-
nant malaria species imported to many European coun-
tries and was associated primarily with immigration 
from sub-Saharan Africa, mainly West Africa and, to 
a lesser extent, with returning travellers who had vis-
ited sub-Saharan Africa, but who failed to use chemo-
prophylaxis [9]. Since 2013, Eritrean asylum seekers 
have changed the profile of imported malaria cases in 
Europe with a shift towards P. vivax. In Germany, prior 
to 2013, 80% of all imported malaria cases, numbering 
500–600 total cases annually were falciparum malaria 
cases, and vivax malaria was a minor contributor 
(approximately 7%) [3]. One study from a large Ham-
burg University hospital saw a relative increase in P. 
vivax malaria from only 2% of all cases in 2013, to 26% 
in 2014, and 34% in 2015. Approximately 95% of these 
vivax cases were in Eritreans [3]. In the Netherlands, 
during the period 2008–2015, P. vivax infections origi-
nated mainly from the Horn of Africa (214/372; 57.5%) 
and were largely attributable to asylum seekers from 
Eritrea [1]. In Milan, northern Italy, the proportion of 
P. vivax cases treated at a referral university hospital 
rose from 14.5% P. vivax in 2013 to 33.3% P. vivax in 
2014 due mainly to malaria cases in Eritrean migrants 
[10]. In Sweden, a significant number of P. vivax cases 
in asylum-seekers from Eritrea led to the largest surge 
in imported malaria cases since computerized record-
ing of malaria cases began in 1986 [4]. Because Sweden 
has accurate denominator data on asylum-seekers, the 
incidence rate of P. vivax in Eritreans was estimated at 
19.5 per 1000 asylum seekers. In those aged less than 
18  years, the incidence rate was considerably higher 
and estimated at 38.2 per 1000 [4].
Time to presentation
The GeoSentinel analysis showed that about 69% of the 
migrants with malaria presented after arrival and the 
median time between arrival in the host country and 
presentation was 39 days (Table 2). Many of the Eritrean 
asylum-seekers had a long, arduous route to Europe 
that may have lasted several months (Fig.  2) and 31% 
reported malaria symptoms while in transit. These may 
have been P. falciparum cases or early onset P. vivax. 
Some strains of P. vivax do not produce primary attacks 
soon after infection and the first clinical symptoms may 
occur several months after the infective bite. Although 
there are few data on vivax time to relapse from Eritrea. 
P. vivax strains from the Horn of Africa have been rec-
ognized to have a long relapse interval [13, 14]. Com-
pared to P. falciparum, regional populations of P. vivax 
exhibit high genomic diversity [15, 16]. The molecular 
epidemiology of P. vivax presenting in Eritrean migrants 
needs further investigation. Another result of late pres-
entation and/or delayed diagnosis is an increased risk 
of severe malaria as evidenced here in this analysis 
Table 3 Clinical features of  the  malaria cases [all 
diagnoses were confirmed except  in  4 patients (two 
P. vivax mono-infections were probable diagnoses, 
and  in  two mixed infections, P. falciparum infection 
was  probable while  P. vivax infection was  confirmed)] 
in Eritrean migrants
a Information available for 100 patients out of 146
b P. vivax infection with severe anaemia (n = 3), P. vivax infection with 
renal failure (n = 1), P. vivax infection with cardiovascular failure (n = 1), P. 
falciparum infection with severe anaemia (n = 1), P. falciparum infection with 
hyperparasitaemia and respiratory failure (n = 1), unknown malaria species 
infection with neurological symptoms (n = 1) and unknown malaria species 
infection with cardiovascular failure (n = 1)
Time of onset in relation to time of arrival in the host 
 countrya
 Onset of symptoms before arrival 31 (31.0%)
 Onset of symptoms after arrival 69 (69.0%)
 Time between arrival date and onset of symptoms in 
patients with onset after arrival (N = 69)
94.9 days (148.9)
 Mean (standard deviation) 39 days (0–721)
 Median (range)
 Time between onset of symptoms and visit date to 
GeoSentinel clinic (N = 69)
9.9 days (19.1)
 Mean (standard deviation) 3 days (0–92)
 Median (range)
Location of care
 Inpatient 96 (65.8%)
 Outpatient 50 (34.2%)
Malaria classification
 Non-severe 137 (93.9%)
 Severe and  complicatedb 9 (6.1%)
Main symptoms
 Fever/sweats/chills 143 (98.0%)
 Gastrointestinal 14 (9.6%)
 Fatigue 12 (8.2%)
 Headaches 11 (7.5%)
 Respiratory 10 (6.9%)
 Neurologic 5 (3.4%)
 Genito-urinary/renal 3 (2.1%)
 Cardiac 2 (1.4%)
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with a 66% hospitalization rate and 9 cases of severe 
malaria. The difficulty of achieving an early, accurate 
diagnosis of vivax malaria, due to low sensitivity of 
both blood smear and malaria rapid diagnostic tests 
(RDTs) remains an issue in clinical practice in Europe 
and delayed diagnosis may have contributed to the high 
proportion of complicated cases, including the severe 
anaemia reported here.
Where was malaria acquired—in Eritrea or in transit?
There are few data available on the epidemiology of 
malaria in Eritrea. Eritrea is located at the most northern 
Malaria Epidemiology along the migration route
Eritrea: Mainly P. falciparum (circa 90%), P. vivax (10%)
Ethiopia: Mainly P.falciparum (> 60%)
Sudan: Mainly P. falciparum (circa 95%) but P.vivax is present especially in the eastern parts of 
Sudan bordering Ethiopia and Eritrea
Egypt: malaria unlikely as Egypt is approaching elimination status
Libya: considered malaria free but migrants from malaria-endemic areas of Africa are gathered 
in camps and competent vectors are present. Malaria transmission can be suspected.
Fig. 2 Map of migration routes from Eritrea overland to Europe and via airlift to the US and Canada and malaria epidemiology on the migration 
paths
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limit of malaria transmission in East Africa. A parasito-
logical, cross-sectional survey published in 2005 [17] 
documented screening and testing of 13,000 individuals 
in 176 villages in Eritrea. Malaria prevalence was low and 
focal and distributed across all age groups (suggesting 
low natural immunity) and P. falciparum was the domi-
nant species (90%). One limitation of the aforementioned 
study was the low sensitivity and specificity of the Opti-
Mal RDT used as the single screening test. Did the study 
miss the local P. vivax while preferentially documenting 
P. falciparum? An independent assessment in 2008 of 
OptiMal for P. vivax malaria found a sensitivity close to 
95% for 200 parasites per microlitre [18] but depending 
on technique the sensitivity was as low as 75% and other 
studies report a much lower sensitivity, especially at low 
grade parasitaemia [19, 20]. Most patients with malaria 
seen in this study and in the studies identified during the 
literature review had P. vivax. This does not reflect the 
local epidemiology in Eritrea as described by Sintasath 
et  al. [17] or that in the latest World Health Organiza-
tion World Malaria Report that shows an approximate 
species prevalence of P. falciparum of 89% in Eritrea [21]. 
This suggests that the acquisition of malaria infection 
occurred later, most probably during the migration route, 
and that falciparum malaria tended to present, and pre-
sumably be treated, en route, prior to arrival in the host 
country. An Israeli report of P. vivax in Eritreans sug-
gested that the most likely place of malaria exposure was 
in refugee camps in eastern Sudan [2]. In this analysis, at 
least 31 of the migrants/asylum seekers transited Ethio-
pia and this region may have been the source of some of 
the infections [22]. In seven cases, Egypt was included in 
the transit route and while this would be an unlikely area 
of acquisition (due to the current malaria elimination sta-
tus) cross-border movements render the area vulnerable 
to re-introduction [23].
From 2000 through 2016 a total of approximately 17,050 
Eritrean refugees and immigrants were admitted into the 
U.S, primarily resettled from camps (Shimelba and Mianey) 
in Ethiopia (Fig.  2). Although Eritrean by ethnicity, only 
41% were born in Eritrea, with approximately 53% being 
born in Ethiopia, and Sudan accounting for the birth coun-
try for the majority of the remainder [24]. These refugees, 
unless they had a contraindication, received pre-depar-
ture anti-malarials prior to leaving Africa for presump-
tive treatment; since 2007, the pre-departure treatment is 
artemether/lumefantrine. Only two US malaria cases (both 
P. vivax) were identified in the GeoSentinel analysis despite 
large numbers of Eritreans resettled in the US suggesting 
that Eritreans with malaria are either not presenting at US 
GeoSentinel sites, or, more likely, are benefitting from pre-
departure evaluations and mass drug administration with 
anti-malarials before direct resettlement to the USA via 
regularized migration pathways (Additional file 1).
This situation suggests that P. vivax occurred later in 
the transit route than the pre-US departure camps in 
Ethiopia because artemether/lumefantrine would not 
prevent the relapse vivax infections that were seen in the 
majority of the cases in Europe. These data highlight the 
importance of understanding the migration journey for 
all resettled migrants and the importance of efforts to 
provide pre-departure treatment at least for falciparum 
malaria. Furthermore, this supports the recommenda-
tion made at the United Nations General Assembly by 
Secretary General Gutierrez that efforts must be made 
to channel refugee movements toward regularized struc-
tured migration and away from chaotic irregular flows. 
This includes the provision of comprehensive health ser-
vices for assessment, screening, treatment and preven-
tion as early in the displacement process as possible.
Libya was also part of the transit route for 34 of the 
cases described here. There is some speculation regarding 
malaria transmission in Libya and hypothesized possible 
acquisition of P. falciparum malaria in Libyan detainment 
camps [25, 26]. In the Libyan camps, migrants are in close 
contact with other refugees including migrants from West 
Africa and it is plausible that malaria may be transmitted 
in these centres. This study identified cases of P. falcipa-
rum (8.2%) and P. ovale (2.7%) in the Eritrean migrants. 
Anopheline mosquitoes are present in Libya including 
Anopheles multicolor, Anopheles sergentii and Anopheles 
labranchiae [27]. These vectors are potentially capable of 
transmitting P. vivax, P. falciparum and P. ovale. Another 
concern further on in the transit route is that there is a 
potential for the reintroduction of malaria in receptive 
European areas. Multiple reports in 2017 have docu-
mented locally acquired malaria, both P. vivax and P. fal-
ciparum, in Greece, Cyprus, France and Italy and these 
have been summarized in an European Centre for Disease 
Control (ECDC) rapid risk assessment report [28]. Even 
further north in temperate Europe, the current situation 
of “Anophelism without malaria” may be threatened by 
large numbers of imported P. vivax malaria in the pres-
ence of competent vectors, such as Anopheles atroparvus, 
Anopheles messeae and Anopheles sacharovi. The capac-
ity for dormancy has allowed P. vivax to be transmitted 
in Europe and North America and other temperate zones 
where the climate is normally prohibitive to transmission 
of other malaria species. Large outbreaks of vivax malaria 
have been reported in temperate zones when vivax 
infected individuals return to temperate areas after expo-
sure in P. vivax endemic regions [29].
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G6PD deficiency testing, primaquine treatment 
and implications for clinical practice
Primaquine treatment, 15(− 30) mg base per day for 
14  days, is indicated to prevent relapses by hypnozo-
ite elimination. Primaquine is contraindicated in G6PD 
severely deficient individuals because of the risk of a 
potentially fatal haemolysis [30]. It is also controversial 
in imported malaria due to all the problems related to 
a considerable number of individuals being mildly-to-
severely G6PD deficient; the adherence to the long-dura-
tion regimen as well as limited ad-hoc availability of the 
drug in many European countries (Additional file 2). The 
same restrictions will apply to the alternative 8-amino-
quinoline, tafenoquine, when it becomes available [31]. 
It is considered standard of care to test for G6PD defi-
ciency in all persons prior to use of primaquine. In case 
of severe G6PD deficiency, less than 10% residual enzy-
matic activity, primaquine should be avoided and the 
risk–benefit balance carefully assessed. In case of mod-
erate deficiency, WHO proposes an 8-week schedule for 
treatment with primaquine: 0.75 mg/base/kg body weight 
once weekly for 8 weeks [32]. A practical problem is that 
the current reference method for G6PD testing is UV 
spectrophotometry. This method requires considerable 
laboratory infrastructure [33]. Inexpensive, highly reli-
able ‘field’, or point-of-care, tests are in development, but 
have not yet reached the level of development needed to 
enter the market [33]. Physicians dealing with imported 
cases of vivax malaria must strive to secure access to pri-
maquine and to pre-empt relapses in their patients after 
having firmly established their G6PD status. Primaquine 
is widely available in Canada and in the USA; it is FDA-
approved for the radical cure (prevention of relapse) of 
vivax malaria. In Switzerland and many EU countries, 
primaquine is only available through hospital pharmacies 
or through an international pharmacy with delays in pro-
curement [34]. The availability of primaquine in is sum-
marized in the Additional file 2.
Malaria detection in the hard‑to‑reach migrant population, 
and possible policy implications
Migrant populations are considered “hard-to-reach” for 
infectious disease care [34, 35] in terms of use and access 
to regular health services and this applies to Eritreans 
who are displaced within prosperous nations in Europe. 
Early diagnosis and correct management of malaria in 
Eritrean migrants will prevent severe disease. The pro-
curement logistics and long therapy duration with pri-
maquine, the need for pre-treatment G6PD screening, in 
an Eritrean population with an allele prevalence of 3–7% 
[36] dictate that a specific policy is needed to address 
malaria in Eritrean migrants.
Strengths and limitations
This is a large descriptive analysis of malaria cases in 
Eritrean asylum-seekers. A major strength of the Geo-
Sentinel database is the global linkage of clinician veri-
fied malaria clinical data with accurate demographics 
and detailed travel history including transit routes. The 
improved GeoSentinel data collection form for migrants 
captures data elements on the status of the migrant (refu-
gee, asylum-seeker) and screening results. GeoSentinel 
analyses constitute a valuable approach to documenting 
epidemiological patterns in mobile populations such as 
migrants. This GeoSentinel study has the limitation that 
denominator data are unavailable and that only a subset 
of all malaria cases in Eritrean migrants were captured. 
Because GeoSentinel sites in Europe are often important 
reference hospitals, this may have led to a bias selecting 
the more severe malaria cases and cases treated else-
where are missed. Only two US cases (both P. vivax) were 
included in this analysis despite large numbers of Eritre-
ans resettled in the US with 4685 individuals registered 
between October 1, 2016 and April 30, 2017, according to 
the Migration Policy Institute [24].
Conclusions
This is the first multi-centre, global study of malaria in 
Eritrean migrants. It is the first study to provide clini-
cal detail on malaria cases, demographics and itinerary 
data on Eritreans presenting at several clinics through-
out Europe. It highlights the need for current or future 
host countries receiving asylum-seekers from Eritrea to 
be prepared for large surges in vivax malaria. The treat-
ment of P. vivax will require complex pre-screening for 
G6PD deficiency and primaquine treatment. This study 
found that primaquine was difficult to procure through-
out Europe and only licensed in North America.
Most importantly, this study highlighted the need 
explore the molecular epidemiology of P. vivax in Eri-
trean asylum-seekers, to investigate the area of acqui-
sition of malaria along common transit routes and to 
determine whether there has been re-introduction of 
malaria in areas, such as Libya, where malaria is con-
sidered eliminated but where capable vectors and plas-
modia co-circulate.
Additional files
Additional file 1. Guidelines for pre-departure presumptive malaria treat-
ment for refugees resettling to the USA from sub-Saharan Africa.
Additional file 2. Availability of primaquine and G6PDH deficiency test-
ing at GeoSentinel sites.
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